15356-60-2: Emtricitabine Impurity 10

15356-60-2: Emtricitabine Impurity 10

Also known as (1S,2R,5S)-(+)-Menthol, (+)-Menthol, (1S,2R,5S)-Menthol or d-Menthol is a nucleoside reverse transcriptase inhibitor (NRTI) in combination with other antiviral agents it shows activity against HIV. It is approved for use in combination therapy.

Additional information on CAS 15356-60-2

Catalogue No.

VL54015
CAS No.

15356-60-2
Molecular Formula

C10H20O
Molecular Weight

156.27
Parent drug

Emtricitabine
IUPAC Name

(1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanol
Synonyms

(1S,2R,5S)-(+)-Menthol; (+)-Menthol; d-Menthol; (1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanol; [1S-(1?, 2?, 5?)]-5-Methyl-2-(1-methylethyl)c;yclohexanol; (1S, 3S, 4R)-(+)-Menthol; (+)-Menthol; (1S, 2R, 5S)-(+)-Menthol; (1S, 2R, 5S)-Menthol; d-Menthol;
References

'Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://do
Status

In-stock

Other products related to emtricitabine

[rfq_list]

Login first to add product to RFQ List

Request a quote

15356-60-2: Emtricitabine Impurity 10

15356-60-2: Emtricitabine Impurity 10
Catalogue No.

VL54015
CAS No.

15356-60-2
Molecular Formula

C10H20O
Molecular Weight

156.27
Parent drug

Emtricitabine
IUPAC Name

(1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanol
Synonyms

(1S,2R,5S)-(+)-Menthol; (+)-Menthol; d-Menthol; (1S, 2R, 5S)-5-Methyl-2-(1-methylethyl)cyclohexanol; [1S-(1?, 2?, 5?)]-5-Methyl-2-(1-methylethyl)c;yclohexanol; (1S, 3S, 4R)-(+)-Menthol; (+)-Menthol; (1S, 2R, 5S)-(+)-Menthol; (1S, 2R, 5S)-Menthol; d-Menthol;
References

'Sax, Paul E., et al. “Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Dolutegravir with Emtricitabine and Tenofovir Alafenamide, for Initial Treatment of HIV-1 Infection (GS-US-380–1490): A Randomised, Double-Blind, Multicentre, Phase 3, Non-Inferiority Trial.” The Lancet, vol. 390, no. 10107, Nov. 2017, pp. 2073–82, https://doi.org/10.1016/s0140-6736(17)32340-1. Bang, Lynne M., and Lesley J. Scott. “Emtricitabine.” Drugs, vol. 63, no. 22, 2003, pp. 2413–24, https://do
Status

In-stock
ListName

Emtricitabine Impurity 10
Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden